2025 Judges | Finals

Meredith Fisher, Partner at MGB Innovation Fund

Meredith Fisher is a Partner with Mass General Brigham Ventures, focusing on early-stage investments and company creation. She brings a wealth of experience from her prior role as Director of Private Investments at Bracebridge Capital, where she led investments in early-stage life science companies. Meredith’s career also includes extensive experience in business development, investing, and technical drug discovery, with key roles at Ginkgo BioWorks, PureTech Ventures, Idenix Pharmaceuticals, and Anadys Pharmaceuticals.

In addition to her professional achievements, Meredith is deeply committed to fostering innovation in the life sciences sector. She holds board positions at FireCyte, Nocion, ClarisBio, and ZielBio, and is a co-founder and board member of Violet, Brave Bio, and Mediar. She also serves as a board observer for Scorpion Therapeutics and Amolyt Pharma, further extending her influence in shaping transformative healthcare ventures.

Meredith’s academic credentials include a PhD from Harvard University, an MBA from the MIT Sloan School of Management, and an undergraduate degree from Mount Holyoke College. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE), demonstrating her commitment to advancing diversity and inclusion in STEM fields.

Angela Hwang, CEO at Flagship Pioneering and CEO at Metaphore Biotechnologies

Angela Hwang is CEO-Partner at Flagship Pioneering and Chief Executive Officer of Metaphore Biotechnologies. Prior to this, Angela collected over 27 years of experience at Pfizer, where she held various leadership roles, including most recently Chief Commercial Officer and President of the Global Biopharmaceuticals Business and member of Pfizer's executive leadership team. In these roles, Hwang and her organization of 26,000 colleagues brought critical therapies in oncology, internal medicine, rare diseases, inflammation and immunology, vaccines, and hospital injectables to patients around the world and led many groundbreaking product launches, including the world's first COVID-19 vaccine and the first oral antiviral treatment. Currently, Hwang also serves on the Board of Directors of UPS.

Hwang is consistently ranked among the world's top leaders in healthcare and business. Fortune placed her as one of The Most Powerful Women in Business four years in a row from 2020 to 2023. In 2021, she received The President's Award from the National Diversity Council and was also named an A100 Honoree which recognizes the most impactful AAPI leaders. In 2022, Cornell University named Hwang a Robert S. Hatfield Economic Fellow. In 2023, she was recognized as an Ascend A-list Honoree for her professional achievements as an Asian American leader and in 2024, Hwang was selected by CNBC as a Changemaker in Business.

Hwang received a BS in Microbiology from the University of Cape Town and an MBA from Cornell University.

Vic Lanio, Partner at Flare Capital Partners

Vic Lanio is a Partner at Flare Capital Partners. Vic led the firm’s investments in Elektra Health, Greater Good Health, and Ounce of Care. In addition, in the past, he held Board observer roles with Aspen RxHealth, Axuall, Circulation (acquired by LogistiCare), Cohere Health, Oui Therapeutics, Tausight, Visana Health, Visitpay (acquired by R1), and Vita Health. He also has led the firm’s Flare Scholars Ventures investments in Marigold Health, Piction Health, and Ounce of Care.

Before joining Flare Capital, Vic held corporate development roles at Curaspan, which was acquired by naviHealth in 2016. After the acquisition, he transitioned to oversee product strategy in the parent company. Vic started his career in healthcare as a hospital system consultant at PwC and McKinsey & Company. He focused primarily on health system strategy within the context of the Affordable Care Act, the transition to value-based care, the revenue cycle, and clinical operations work. At McKinsey, he worked on the Objective Health team, a tech-enabled consulting model for small to mid-sized health systems. He also helped launch and served as the President and Executive Board Chair of Boston Young Healthcare Professionals, a 501(c)(3) organization aimed at providing educational, networking, and community service opportunities for young healthcare professionals in Boston.

Vic obtained his undergraduate degree from Boston College, with majors in Physics and Management with a Concentration in Finance. He also obtained his MBA from the MIT Sloan School of Management. While completing his MBA, Vic co-directed the inaugural MIT Healthcare Innovations Prize in 2016.

Rene Mora, Portfolio Manager at Monashee Investment Management

Dr. Rene Mora has served as Portfolio Manager at Monashee Investment Management since 2020, where he oversees healthcare investments in public and private companies. In this role, he leverages his extensive expertise in healthcare and finance to identify high-impact investment opportunities within the sector. Prior to Monashee, Dr. Mora was Chief Scientific Officer at Leerink Partners from 2000 to 2020. There, he collaborated with the Corporate Finance group on due diligence for financing transactions and mergers & acquisitions and structured proprietary research projects for corporate banking clients.

Dr. Mora's academic journey began at Brown University, followed by earning a Ph.D. in Biochemistry and an M.D. from the University of Chicago. He completed board certifications in Internal Medicine, Pulmonary Diseases, and Critical Care Medicine and held leadership roles in medicine, including as Director of the Medical Intensive Care Unit at Beth Israel Deaconess Medical Center and Associate Physician at Brigham and Women’s Hospital. He also served as an Instructor in Medicine at Harvard Medical School, publishing over 30 manuscripts in medical journals and textbooks.

Dr. Mora’s transition from medicine to finance exemplifies his ability to translate clinical expertise into strategic investment insights. He has shared his multidisciplinary experience through educational initiatives, including seminars on the intersection of research, finance, and healthcare. 

2025 SHIP Judges | Semi-Finals